[1]
|
B. Eriksson, K. Oberg and M. Stridsberg, “Tumor Markers in Neuroendocrine Tumors,” Digestion, Vol. 62, Suppl. 1, 2000, pp. 33-38.
http://dx.doi.org/10.1159/000051853
|
[2]
|
W.E. Schmidt, E.G. Siegel, H. Kratzin and W. Creutzfeldt W, “Isolation and Primary Structure of Tumor-Derived Peptides Related to Human Pancreastatin and Chomogranin A,” Proceedings of the National Academy of Sciences of the United States, Vol. 85, No. 21, 1988, pp. 8231-8235. http://dx.doi.org/10.1073/pnas.85.21.8231
|
[3]
|
E. Raymond, L. Dahan, J.-L. Raoul, Y.-J. Bang, I. Borbath, C. Lombard-Bohas, J. Valle, P. Metrakos, D. Smith, A. Vinik, J.-S. Chen, D. Horsch, P. Hammel, B. Wiedenmann, E. Van Cutsem, S. Patyna, D.R. Lu, C. Blanckmeister, R. Chao and P. Ruszniewski, “Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors,” The New England Journal of Medicine, Vol. 364, 2011, pp. 501-513. http://dx.doi.org/10.1056/NEJMoa1003825
|
[4]
|
J. C. Yao, M. H. Shah, T. Ito, C. L. Bohas, E. M. Wolin, E. Van Cutsem, T.J. Hobday, T. Okusaka, J. Capdevila, E. G. E. de Vries, P. Tomassetti, M. E. Pavel, S. Hoosen, T. Haas, J. Lincy, D. Lebwohl and K. Oberg, “Everolimus for Advanced Pancreatic Neuroendocrine Tumors,” The New England Journal of Medicine, Vol. 364, 2011, pp. 514-523. http://dx.doi.org/10.1056/NEJMoa1009290
|
[5]
|
G. Kloppel, P. A. Intveld, B. Stamm and P. U. Heitz, “The Endocrine Pancreas,” In: K. Kovacs and S. L. Asa, Eds., Functional Endocrine Pathology, Blackwell Scientific Publications, Boston, 1990, pp. 396-421.
|
[6]
|
T. Shibue, K. Takeda, E. Oda, H. Tanaka, H. Murasawa, A. Takaoka, Y. Morishita, S. Akira, T. Taniguchi and N. Tanaka, “Integral Role of Noxa in p53-Mediated Apoptotic Response,” Genes & Development, Vol. 17, 2003, pp. 2233-2238. http://dx.doi.org/10.1101/gad.1103603
|
[7]
|
J.-Z. Qin, J. Ziffra, L. Stennett, B. Bodner, B. K. Bonish, V. Chaturvedi, F. Bennett, P. M. Pollock, J. M. Trent, M. J. C. Hendrix, P. Rizzo, L. Miele and B. J. Nickoloff, “Proteasome Inhibitors Trigger NOXA-Mediated Apoptosis in Melanoma and Myeloma Cells,” Cancer Research, Vol. 65, 2005, pp. 6282-6293.
http://dx.doi.org/10.1158/0008-5472.CAN-05-0676
|
[8]
|
Y. Fernandez, M. Verhaegen, T. P. Miller, J. L. Rush, P. Steiner, A. W. Opipari, S. W. Lowe and M. S. Soengas, “Differential Regulation of Noxa in Normal Melanocytes and Melanoma Cells by Proteasome Inhibition: Therapeutic Implications,” Cancer Research, Vol. 65, 2005, pp. 6294-6304.
http://dx.doi.org/10.1158/0008-5472.CAN-05-0686
|
[9]
|
E. P. Slater, V. Fendrich, J. Waldmann, E. Nalbatow, B. Chaloupka and D. K. Bartsch, “Down-regulation of the Noxa Gene in Gastrinomas,” Experimental and Clinical Endocrinology & Diabetes, 2006.
|
[10]
|
A. K. Jansson, A. M. Emterling, G. Arbman and X.-F. Sun, “Noxa in Colorectal Cancer: A Study on DNA, mRNA and Protein Expression,” Oncogene, Vol. 22, 2003, pp. 4675-4678.
http://dx.doi.org/10.1038/ sj.onc.1206655
|
[11]
|
G. Rindi and G. Kloppel, “Endocrine Tumors of the Gut and Pancreas Tumor Biology and Classification,” Neuroendocrinology, Vol. 80, Suppl. 1, 2004, pp. 12-15.
http://dx.doi.org/10.1159/ 000080733
|
[12]
|
E. P. Slater, S. M. Diehl, P. Langer, B. Samans, A. Ramaswamy, A. Zielke and D. K. Bartsch, “Analysis by cDNA Microarrays of Gene Expression Patterns of Human Adrenocortical Tumors,” European Journal of Endocrinology, Vol. 154, 2006, pp. 587-598.
http://dx.doi.org/10.1530/eje.1.02116
|
[13]
|
B. M. Evers, J. Ishizuka, C. M. Townsend and J. C. Thompson, “The Human Carcinoid Cell Line, BON,” Annals of the New York Academy of Sciences, Vol. 733, 1994, pp. 393-406.
http://dx.doi.org/10.1111/ j.1749-6632.1994.tb17289.x
|
[14]
|
M. A. Nikiforov, M. Riblett, W. H. Tang, V. Gratchouck, D. Zhuang, Y. Fernandez, M. Verhaegen, S. Varambally, A. M. Chinnaiyan, A. J. Jakubowiak and M. S. Soengas, “Tumor Cell-Selective Regulation of NOXA by c-MYC in Response to Proteasome Inhibition,” Proceedings of the National Academy of Sciences of the United States, Vol. 104, No. 9, 2007, pp. 19488-19493.
http://dx.doi.org/ 10.1073/pnas.0708380104
|
[15]
|
S. T. Nawrocki, J. S. Carew, K. H. Maclean, J. F. Courage, P. Huang, J. A. Houghton, J. L. Cleveland, F. J. Giles and D. J. McConkey, “Myc Regulates Aggresome Formation, the Induction of Noxa, and Apoptosis in Response to the Combination of Bortezomib and SAHA,” Blood, Vol. 112, No. 7, 2008, pp. 2917-2926.
http://dx.doi.org/10.1182/blood-2007-12-130823
|
[16]
|
J. Voortman, A. Checinska, G. Giaccone, J. A. Rodriguez and F. A. E. Kruyt, “Bortezomib, but not Cisplatin, Induces Mitochondria-Dependent Apoptosis Accompanied by Up-Regulation of Noxa in the Non-Small Cell Lung Cancer Cell Line NCI-H460,” Molecular Cancer Therapeutics, Vol. 6, No. 3, 2007, pp. 1046-1053.
http://dx.doi.org/10.1158/1535-7163.MCT-06-0577
|
[17]
|
D. Lindberg, O. Hessman, G. Akerstr?m and G. Westin, “Cyclin-Dependent Kinase 4 (CDK4) Expression in Pancreatic Endocrine Tumors,” Neuroendocrinology, Vol. 86, 2007, pp. 112-118. http://dx.doi.org/10.1159/000106762
|
[18]
|
I. Arany, P. Rady, B. M. Evers, S. K. Tyring and C. M. Townsend, “Analysis of Multiple Molecular Changes in Human Endocrine Tumours,” Surgical Oncology, Vol. 3, No. 3, 1994, pp. 153-159.
http://dx.doi.org/10.1016/0960-7404(94)90044-2
|
[19]
|
D. E. Larsson, M. Wickstrom, S. Hassan, K. Oberg and D. Granberg, “The Cytotoxic Agents NSC-95397, Brefeldin A, Bortezomib and Sanguinarine Induce Apoptosis in Neuroendocrine Tumors in Vitro,” Anticancer Research, Vol. 30, No. 1, 2010, pp. 149-156.
|